Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first‐in‐human phase I study
Cancer Science · 2025
DOI: 10.1111/cas.16354 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Science, 2025. Verfasst von Chigusa Morizane und 26 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Stomach Neoplasms, Bile Duct Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai.
Abstract (Originalsprache)
Fibroblast growth factor receptors (FGFRs) are a highly conserved family of transmembrane receptor tyrosine kinases with multiple roles in the regulation of key cellular processes. Specific FGFR mutations have been observed in several types of cancers, including gastric carcinoma and cholangiocarcinoma. Dose escalation data of 24 Japanese patients with solid tumors treated with Tasurgratinib (previously known as E7090), a potent, selective FGFR1–3 inhibitor, was reported in a phase I, first‐in‐human, single‐center study. Based on the safety, pharmacokinetic, and pharmacodynamic profiles observed in this study, the recommended dose of 140 mg once daily was selected for the expansion part (Part 2), a multicenter expansion of the dose‐finding study restricted to patients with tumors harboring FGFR gene alterations. Safety and preliminary efficacy were assessed in Part 2. Pharmacodynamic pharmacogenomic markers (serum phosphate, FGF23, and 1,25‐(OH) 2 ‐vitamin D, circulating tumor DNA) and pharmacokinetic profiles were also evaluated. A total of 16 patients were enrolled in Part 2, six with cholangiocarcinoma and 10 with gastric cancer. The most common treatment‐emergent adverse events were hyperphosphatemia, palmar‐plantar erythrodysesthesia syndrome, and paronychia. Five partial responses (83.3%) in cholangiocarcinoma patients and one partial response (11.1%) in gastric cancer patients were observed; median progression‐free survival was 8.26 months (95% confidence interval [CI] 3.84, not evaluable [NE]) and 3.25 months (95% CI 0.95, 4.86), and overall survival was 22.49 months (95% CI 6.37, NE) and 4.27 months (95% CI 2.23, 7.95), respectively, in the two groups. In conclusion, Tasurgratinib 140 mg has a tolerable safety profile with good clinical efficacy in patients with cholangiocarcinoma harboring FGFR2 gene rearrangements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Cancer Center Hospital, Tokyo, Japan.
- Kanagawa Cancer Center, Yokohama, Japan.
- Oncology Center, Yamaguchi University Hospital, Ube, Japan.
- Aichi Cancer Center Hospital, Nagoya, Japan.
- National Cancer Center Hospital East, Kashiwa, Japan.
- The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Masafumi Ikeda, Satoru Iwasa, Manabu Muto, Yoshito Komatsu, Masakazu Yashiro
Förderung
- Eisai
Zitieren
APA
Morizane, C., Ueno, M., Ioka, T., Tajika, M., Ikeda, M., Yamaguchi, K., Hara, H., Yabusaki, H., Miyamoto, A., Iwasa, S., Muto, M., Takashima, T., Minashi, K., Komatsu, Y., Nishina, T., Nakajima, T. E., Takeno, A., Moriwaki, T., Furukawa, M., …, & Furuse, J. (2025). Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first‐in‐human phase I study. Cancer Science. https://doi.org/10.1111/cas.16354
Vancouver
Morizane C, Ueno M, Ioka T, Tajika M, Ikeda M, Yamaguchi K, et al. Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first‐in‐human phase I study. Cancer Science. 2025. doi:10.1111/cas.16354
BibTeX
@article{Morizane2025,
author = {Morizane, Chigusa and Ueno, Makoto and Ioka, Tatsuya and Tajika, Masahiro and Ikeda, Masafumi and Yamaguchi, Kensei and Hara, Hiroki and Yabusaki, Hiroshi and Miyamoto, Atsushi and Iwasa, Satoru and Muto, Manabu and Takashima, Tsutomu and Minashi, Keiko and Komatsu, Yoshito and Nishina, Tomohiro and Nakajima, Takako Eguchi and Takeno, Atsuchi and Moriwaki, Toshikazu and Furukawa, Masayuki and Sahara, Takatoshi and Ikezawa, Hiroki and Nomoto, Maiko and Takashima, Shuya and Uehara, Taisuke and Funasaka, Setsuo and Yashiro, Masakazu and Furuse, Junji},
title = {Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first‐in‐human phase I study},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16354}
}
EUVIMED